Brief: Elevation Oncology Expands Pipeline With Nomination Of EO-1022
12/12/2024 12:47
Dec 12 (Reuters) - Elevation Oncology ELEV.O :
* ELEVATION ONCOLOGY EXPANDS PIPELINE WITH NOMINATION OF
EO-1022,
A HER3 ADC FOR THE TREATMENT OF HER3-EXPRESSING SOLID TUMORS
* ELEVATION ONCOLOGY INC: EXPECTS TO PRESENT EO-1022
PRECLINICAL
DATA IN 1H 2025 AND TO FILE AN IND APPLICATION IN 2026
Source text: ID:nPn2QMcL4a
Further company coverage: ELEV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Elevation Oncology
See all newsBrief: Elevation Oncology Terminates License Agreement With CSPC Megalith Biopharmaceutical
U.S. RESEARCH ROUNDUP- Crane, Ryder System, Terex
Brief: Elevation Oncology Says Concentra To Buy Elevation Oncology For $0.36 Per Share Plus CVR
Elevation Oncology Inc expected to post a loss of 19 cents a share - Earnings Preview
Brief: Elevation Oncology Inc - To Prepay Term Loan Under Loan & Security Agreement Dated July 27, 2022 - SEC Filing